Ticagrelor (Brilinta) is a P2Y12 receptor antagonist antiplatelet medication that plays a crucial role in the treatment of acute coronary syndrome (ACS) and old myocardial infarction. As a strictly regulated prescription drug, its acquisition and use must comply with rigorous medical standards.
How to Purchase Ticagrelor (Brilinta)
Overseas Purchase
Patients may consult and purchase ticagrelor at hospital pharmacies or legitimate drugstores in countries/regions where the medication is marketed.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients should make budgetary plans in advance.
Purchase through Medical Service Institutions
Patients may consult domestic overseas medical service institutions collaborating with international pharmacies or pharmaceutical companies.
These institutions typically provide legal import channels and offer professional consultation and guidance.
Precautions for Purchase and Use of Ticagrelor (Brilinta)
Prescription and Dosage Management
Acute Coronary Syndrome (ACS): For adults, the initial dose is 180 mg, followed by a maintenance dose of 90 mg orally twice daily.
Old Myocardial Infarction: For adults, the dose is 60 mg orally twice daily.
Administration Specifications: Must be used in combination with aspirin (maintenance dose: 81–100 mg/day).
Contraindicated Populations
Patients with active bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding, urinary tract bleeding).
Patients with a history of intracranial hemorrhage.
Patients with moderate or severe hepatic impairment.
Patients with hypersensitivity to any component of this medication.
Patients currently taking strong CYP3A inhibitors or inducers.
Usage Restrictions in Special Populations
Hepatic Impairment: Use with caution in patients with mild to moderate impairment; contraindicated in severe impairment.
Renal Abnormalities: Enhanced monitoring for bleeding risk is required.
Elderly Patients: Due to age-related decline in physiological function, dosage adjustment and close monitoring are necessary.
Drug Interaction Management
Strong CYP3A Inhibitors: Itraconazole, voriconazole, clarithromycin, etc.
Anticoagulants: Warfarin, heparin, etc.—may increase bleeding risk.
Other Antiplatelet Drugs: Increase the incidence of bleeding complications.
Authentication of Ticagrelor (Brilinta) Authenticity
Characteristics of the 60 mg Strength
Appearance: Round, film-coated tablets, very pale yellowish-red.
Dimensions: Approximately 8.1 mm in diameter and 3.8 mm in thickness.
Weight: Approximately 0.21 g.
Identification Code: 60T.
Characteristics of the 90 mg Strength
Appearance: Round, film-coated tablets, pale yellow.
Dimensions: Approximately 9.2 mm in diameter and 4.6 mm in thickness.
Weight: Approximately 0.31 g.
Identification Code: 90T.
Identification of Quality Abnormalities
Changes in Properties: Discontinue use immediately if abnormal tablet color, moisture, or caking is observed.
Storage Conditions: Store at room temperature, protecting from moisture.
